Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Hydroxyzine for generalised anxiety disorder

Open access
Guaiana, Giuseppe, Barbui, Corrado, Cipriani, Andrea·2010·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Generalised anxiety disorder (GAD) is a common chronic long-term psychiatric disorder, particularly frequent in primary care. There are several treatment options available, both non-pharmacological (i.e. cognitive behavioral therapy) and pharmacological. Among the pharmacological interventions, antidepressants, buspirone and benzodiazepines (BDZs) have been studied in GAD. Hydroxyzine is an anti-histamine medication which has been used in the treatment of anxiety. OBJECTIVES: 1. To determine the efficacy of hydroxyzine in comparison with placebo or any other active agent in alleviating the acute symptoms of GAD. 2. To review acceptability of treatment with hydroxyzine in comparison with placebo or any other active agent. 3. To investigate the adverse effects of hydroxyzine in comparison with other active agents. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 1 March 2010. The author team ran complementary searches on MEDLINE, CINAHL and PsycINFO and checked reference lists of included studies, previous systematic reviews and major textbooks of anxiety disorders. Personal communication with pharmaceutical companies and experts in the field was also undertaken. SELECTION CRITERIA: Randomised controlled trials allocating patients with GAD to hydroxyzine versus placebo and/or any other anxiolytic agent. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (such as the number of patients who responded to treatment or remitted), acceptability (the number of patients who failed to complete the study) and tolerability (side effect profile). MAIN RESULTS: The search yielded 39 studies. We included five studies in the review with a total of 884 participants. We excluded 31 studies and designated three as awaiting assessment. The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD (odds ratio (OR) 0.30, 95% CI 0.15 to 0.58) and that it is also acceptable/tolerable (OR 1.00, 95% CI 0.63 to 1.58) (OR 1.49, 95% CI 0.92 to 2.40). Compared to other anxiolytic agents (benzodiazepines and buspirone), hydroxyzine was equivalent in terms of efficacy, acceptability and tolerability (hydroxyzine vs chloridiazepoxide: OR 0.75, 95% CI 0.35 to 1.62; hydroxyzine vs buspirone efficacy OR 0.76, 95% CI 0.40 to 1.42). In terms of side effects, hydroxyzine was associated with a higher rate of sleepiness/drowsiness than the active comparators (OR 1.74, 95% CI 0.86 to 3.53). There was, however, a high risk of bias in the included studies. AUTHORS' CONCLUSIONS: The included studies did not report on all the outcomes that were pre-specified in the protocol for this review. Even though more effective than placebo, due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first-line treatment in GAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006815.pub2

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 37 references

Research works printed but not linked: 44

  1. Goldberg, 1973, The use of hydroxyzine (Vistaril) in the treatment of anxiety neurosis, Psychosomatics, 14, 38, 10.1016/S0033-3182(73)71372-4 · doi:10.1016/s0033-3182(73)71372-4
  2. Rickels, 1970, Hydroxyzine and chlordiazepoxide in anxious neurotic outpatients: a collaborative controlled study, Comprehensive Psychiatry, 5, 457, 10.1016/0010-440X(70)90006-4 · doi:10.1016/0010-440x(70)90006-4
  3. Barranco, 1977, Treatment of anxiety with oral hydroxyzine: an overview, Current Therapeutic Research, 22, 217
  4. Breslow, 1968, Evaluation of hydroxyzine pamoate concentrate as an ataractic: double-blind crossover study in a neurotic male prison group, Current Therapeutic Research, 10, 421
  5. Burrell, 1960, Hydroxyzine hydrochloride and chlorpromazine: a clinical trial with a group of "tense" psychiatric patients, Canadian Psychiatric Association Journal, 5, 124, 10.1177/070674376000500212 · doi:10.1177/070674376000500212
  6. Choussat, 1984, Clinical study of hydroxyzine in somatic and psychic manifestations of anxiety, La Vie Medicale, 26, 1157
  7. Brabander, 1990, Effect of hydroxyzine on attention and memory, Human Psychopharmacology, 5, 357, 10.1002/hup.470050408 · doi:10.1002/hup.470050408
  8. Dolan, 1958, Management of emotional disturbances: use of hydroxyzine (Atarax) in general practice, California Medicine, 88, 443
  9. Ende, 1956, Clinical evaluation of Atarax: a non-barbiturate calming agent, Virginia Medical Monthly, 83, 503
  10. Farah, 1956, Preliminary study on the use of hydroxyzine in psychosomatic affections, International Records of Medicine and GP Clinics, 1, 379
  11. Ferreri, 1994, Advantages of hydroxyzine in generalized anxiety disorder : A double-blind controlled versus placebo study, L'Encephale, 20, 785
  12. Garber, 1958, Management of tension and anxiety states with hydroxyzine hydrochloride, Journal of the Florida Medical Association, 45, 549
  13. Hantouche, 1995, Example of hydroxyzine with detailed analysis of its anxiolytic effects on the FARD scale, Nervure, 8, 10
  14. Hantouche, 1999, Interactions between psychotherapy and drug therapy in Generalized Anxiety Disorder, Human Psychopharmacology, 14, S87, 10.1002/(SICI)1099-1077(199908)14:1+<S87::AID-HUP122>3.0.CO;2-F · doi:10.1002/(sici)1099-1077(199908)14:1+<s87::aid-hup122>3.0.co;2-f
  15. Karakostas, 1990, Anxiolysis as a modifying factor of certain neuropsychiatric parameters in patients with coronary heart disease: a double blind placebo-controlled trial of hydroxyzine hydrochloride, Acta Therapeutica, 14, 381
  16. Lader, 1999, Anxiolytic effect of hydroxyzine: a double blind trial versus placebo and buspirone, Human Psychopharmacology, 14, S94, 10.1002/(SICI)1099-1077(199908)14:1+<S94::AID-HUP123>3.0.CO;2-K · doi:10.1002/(sici)1099-1077(199908)14:1+<s94::aid-hup123>3.0.co;2-k
  17. Levis, 1957, Pharmcological study on hydroxyzine, U.C.B. 492; a disubstituted piperazine derivative, Archives Internationals de Pharmacodynamie e de Therapie, 109, 127
  18. Lipton, 1961, High dosages of hydroxyzine in out-patient treatment of severe neuroses and psychoses, The Pennsylvania Medical Journal, 64, 60
  19. Pishkin, 1967, Stress: psychophysiological and cognitive indices in an acute double-blind study with hydroxyzine in psychiatric patients, Archives of General Psychiatry, 16, 471, 10.1001/archpsyc.1967.01730220083012 · doi:10.1001/archpsyc.1967.01730220083012
  20. Reisner, 1967, Hydroxyzine for controlling postpartum anxiety: a double-blind study, Nebraska State Medical Journal, 52, 498
  21. Rickels, 1966, Compliance and improvement in drug-treated and placebo treated neurotic outpatients, Archives of General Psychiatry, 14, 631, 10.1001/archpsyc.1966.01730120071009 · doi:10.1001/archpsyc.1966.01730120071009
  22. Rickels, 1971, Prognostic indicators of 4-week clinical improvement with chlordiazepoxide and hydroxyzine in anxious neurotic outpatients, International Pharmacopsychiatry, 6, 249
  23. Robinson, 1957, Hydroxyzine hydrochloride (Atarax): a new tranquillizer, Southern Medical Journal, 50, 1282, 10.1097/00007611-195710000-00015 · doi:10.1097/00007611-195710000-00015
  24. Samuelian, 1995, Effects on cognitive functions by two anxiolytic treatments on patients with generalized anxiety disorder, L'Encephale, 21, 147
  25. Settel, 1957, Observations on the use of hydroxyzine in anxiety-tension states and senile agitation, American Practitioner, 8, 1584
  26. Shalowitz, 1956, Hydroxyzine: a new therapeutic agent for senile anxiety states; a preliminary report, Geriatrics, 11, 312
  27. Shalowitz, Evaluation of an ataraxic: hydroxyzine in long term therapy, 1961, 174, 357
  28. Silver, 1969, Hydroxyzine, amitriptyline and their combination in the treatment of psychoneurotic patients, Current Therapeutic Research 1969, 11, 663
  29. Smigel JO. Lowe, 1959, Emotional and psychic problems of institutionalized geriatric patients: evaluation of hydroxyzine, Journal of the American Geriatric Society, 7, 61, 10.1111/j.1532-5415.1959.tb00580.x · doi:10.1111/j.1532-5415.1959.tb00580.x
  30. Weber, 1987, Hydroxyzine, sedation of anxiety and functional symptomatology: a collaborative study, Agressologie, 28, 37
  31. Clyne, 1968, A comparative trial between two tranquillizers, The Practitioner, 10, 421
  32. Mock, 1965, A clinical evaluation of hydroxyzine and placebo in anxious psychiatric outpatients, International Journal of Neuropsychiatry, 1, 168
  33. Rzewuska, 2003, [A multicentre double-blind study investigating the anxiolitic efficacy of diazepam, hydroxyzine and tofisopam in patients with generalized anxiety], Farmakoterapia w Psychiatrii i Neurologii [Pharmacotherapy in Psychiatry and Neurology], 3, 53
  34. Saint-Laurent, 1977, Doxepin in the treatment of neuroses: a comparative clinical study of doxepin, chlordiazepoxide, hydroxyzine, meprobamate and phenobarbital, Current Therapeutic Research, 22, 316
  35. Sterlin, 1972, The place of doxepin among the anxiolytic-sedative drugs, Current Therapeutic Research, 14, 195
  36. American Psychiatric Association, 1980, Diagnostic and statistical manual of mental disorders - DSM-III
  37. Barranco, 1977, Treatment of anxiety with oral hydroxyzine: an overview, Current Therapeutic Research, 22, 217
  38. Caycedo, 2001, Generalised anxiety disorder, 187, 10.1002/0470846437.ch10 · doi:10.1002/0470846437.ch10
  39. Griez, 2001, Anxiety Disorders, 10.1002/0470846437 · doi:10.1002/0470846437
  40. Papadopoulous, 1990, Anxiolysis as a modifying factor of certain neuropsychiatric parameters in patients with coronary heart diseases, Neurologie Psychiatrie, April, 7
  41. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
  42. Shalowitz, 1961, Evaluation of an ataraxic (hydroxyzine) in long-term therapy, International Records in Medicine, 174, 367
  43. World Health Organization, 1978, The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)
  44. World Health Organization, 1992, The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)

Cited by

See all 272

Metadata

Authors
Guaiana, G., Barbui, C., & Cipriani, A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-12-08
Volume
2010
Issue
12
Pages
CD006815-CD006815
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1746481573
Cited by
272
References
37
FWCI
7.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hydroxyzine for generalised anxiety disorder. https://app.cochat.ai/papers/10.1002/14651858.cd006815.pub2
The paper
Guaiana, G., Barbui, C., & Cipriani, A. (2010). Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006815.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.